Business
Development of ImmunoBody® Vaccine
Development of ImmunoBody® Vaccine.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9671Z Scancell Holdings Plc 02 June 2016 \n\n02 June 2016\n \nScancell Holdings Plc\n(\"Scancell\" or the \"Company\")\n \nImmunoBody® vaccine to be developed for the treatment of glioblastoma multiforme\n \nResearch undertaken by scientists at Nottingham Trent University and the University of Portsmouth\n \nScancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that researchers at Nottingham Trent University and the University of Portsmouth have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme (GBM) by utilising Scancell's ImmunoBody® technology platform. \n \nGBM is the most common and aggressive form of glioma and carries a very poor prognosis. Around 5,000 people are diagnosed with a primary malignant brain tumour in the UK each year and GBM accounts for just over half of them. Treatments are limited and even with intensive chemotherapy patients have an average survival time of just 14 months. \n \nDue to the highly aggressive nature of GBM and the lack of successful curative treatments to date, there is an urgent need for novel therapeutic approaches such as immunotherapy.\n \nBy using Scancell's ImmunoBody® technology platform, scientists at Nottingham Trent University and the University of Portsmouth are aiming to develop a vaccine that stimulates protective immune responses against tumour molecules such as 'HAGE' and 'TRP2', which are proteins that are expressed in the cancer cells of GBM patients. \n \nThe vaccine treatment will be assessed for its ability to generate strong anti-GBM tumour immunity, as well as the ability to reduce and eradicate established tumours.\n \nThe researchers will also determine whether the vaccine stimulates HAGE and/or TRP2-specific immune cells in the blood of GBM patients that are capable of recognising the GBM tumours. This will demonstrate the ability of a patient's immune system to identify and kill the cancer cells, providing insight into the effectiveness of the treatment. \n \nThe £95,000 study is being funded by the Headcase Cancer Trust, the only UK charity which dedicates its funding solely to research which aims to find a cure for GBM brain tumours. \n \nProfessor Lindy Durrant, Chief ...